{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:08Z","timestamp":1791953168909,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.023","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:23:39Z","timestamp":1790609019000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["To test or not to test: Indications and actionability in lipid genetics"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jacl.2026.09.023_bib1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.023_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pathol.2018.10.014","article-title":"The role of genetic testing in dyslipidaemia","volume":"51","author":"Berberich","year":"2019","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.023_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOL.0000000000000690","article-title":"Can genetic testing help in the management of dyslipidaemias?","volume":"31","author":"Lazarte","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.023_bib4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.09.023_bib5","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.jacl.2026.09.023_bib6","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.023_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.023_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","volume":"110","author":"Spagnuolo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.023_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2026.09.023_bib10","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.023_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.023_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.023_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"N Engl J Med"},{"issue":"9874","key":"10.1016\/j.jacl.2026.09.023_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2026.09.023_bib15","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1161\/ATVBAHA.120.313065","article-title":"2019 George Lyman Duff Memorial Lecture: three decades of examining DNA in patients with dyslipidemia","volume":"40","author":"Hegele","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.023_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14737159.2017.1332997","article-title":"Recent advances in genetic testing for familial hypercholesterolemia","volume":"17","author":"Iacocca","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.023_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1194\/jlr.D045963","article-title":"LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias","volume":"55","author":"Johansen","year":"2014","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.023_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/gim.2016.40","article-title":"A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation","volume":"18","author":"Hunter","year":"2016","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.023_bib19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.023_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101454","article-title":"ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics","volume":"27","author":"Lee","year":"2025","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.023_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.023_bib22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of variant reclassification following hereditary cancer genetic testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.023_bib23","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care","volume":"20","author":"Tandy-Connor","year":"2018","journal-title":"Genet Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:04:16Z","timestamp":1791950656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S1933287426005337"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.023","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To test or not to test: Indications and actionability in lipid genetics","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}